Our Faculty

Scott R. Beach, M.D.

Scott R. Beach, M.D.

Psychiatrist & Medical Editor,
Psychopharmacology Institute

Biography

Scott R. Beach, M.D., is an Associate Professor of Psychiatry at Harvard Medical School (HMS) and former Program Director of the Massachusetts General Hospital (MGH)/McLean Hospital Adult Psychiatry Residency. He received his undergraduate and medical degrees from the University of Virginia (UVA), where he also completed his psychiatry residency. He then completed a Consultation-Liaison Psychiatry Fellowship at MGH and pursued a Dupont-Warren Research Fellowship as part of the MGH Cardiac Psychiatry Research Program (CPRP).

Clinically, Dr. Beach has worked as an attending physician in the psychiatric emergency department and on inpatient consultation services since 2011. His areas of clinical expertise include QT prolongation associated with psychiatric medications, catatonia and related syndromes, the neuropsychiatric effects of COVID-19, and the evaluation of patients who deceive providers.

Publications of Scott R. Beach, M.D.

Quick Take Vol. 91

0.75 CMEs
How do estrogen and hormonal status shape psychosis treatment in women? Which GLP-1 agonist works best for antipsychotic weight gain? Do newer antipsychotics beat aripiprazole for bipolar maintenance? Does low-dose lithium slow decline in mild cognitive impairment? When is ketogenic therapy reasonable in serious mental illness?
Faculty: Amanda Koire, M.D., Ph.D., Oliver Freudenreich, M.D., F.A.C.L.P., James Phelps, M.D., Scott R. Beach, M.D., Derick E. Vergne, M.D.
41.37 minutes in 5 audio sections

Cardiac Side Effects of Psychiatric Medications

1.25 CMEs
A practical review of cardiac side effects across psychiatric medications: heart rate and blood pressure changes, QT prolongation with antipsychotics and antidepressants, IV haloperidol recommendations, clozapine myocarditis and cardiomyopathy monitoring, ADHD medication safety, and a risk-benefit framework for EKG monitoring beyond rigid QTc cutoffs.
Scott R. Beach, M.D.
Harvard Medical School
75.59 minutes in 11 sections

Quick Take Vol. 90

0.75 CMEs
Does prenatal antidepressant exposure cause autism or ADHD in offspring? How do you weigh cardiac risk when combining an antipsychotic and SSRI? When should you rechallenge a patient with clozapine after neutropenia? Should schizophrenia be renamed? Does adding ashwagandha to melatonin improve sleep more than either agent alone?
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P., Derick E. Vergne, M.D., Amanda Koire, M.D., Ph.D., Scott R. Beach, M.D.
47.15 minutes in 5 audio sections

Quick Take Vol. 89

0.50 CMEs
Can antipsychotics help prevent catatonia relapse? Which adjunctive antipsychotic performs best for treating major depression? What do updated antipsychotic efficacy rankings mean for practice in schizophrenia? Are GLP-1 receptor agonists safe for patients with comorbid anxiety? Does varenicline help patients quit vaping?
Faculty: Scott R. Beach, M.D., James Phelps, M.D., Oliver Freudenreich, M.D., F.A.C.L.P., Derick E. Vergne, M.D., David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M.
35.33 minutes in 5 audio sections

Quick Take Vol. 88

0.75 CMEs
Must antipsychotics always be avoided in catatonia? Should you prescribe antidepressants in bipolar depression? Should clozapine start after just one failed antipsychotic trial? Is atypical depression a distinct subtype that resists standard antidepressants? Does soft drink intake worsen depression?
Faculty: Scott R. Beach, M.D., James Phelps, M.D., Oliver Freudenreich, M.D., F.A.C.L.P., Derick E. Vergne, M.D., Paul Zarkowski, M.D.
38.52 minutes in 5 audio sections

Quick Take Vol. 85

0.50 CMEs
Does Cobenfy maintain its efficacy and safety after one year of use? Should we reconsider trazodone for depression-associated insomnia despite AASM guidelines? Is antidepressant monotherapy in bipolar I as risky as previously thought? Does inflammation explain treatment resistance in older depressed adults? What risk factors predict stimulant misuse and diversion in ADHD patients?
Faculty: Scott R. Beach, M.D., Oliver Freudenreich, M.D., F.A.C.L.P., David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., James Phelps, M.D., Paul Zarkowski, M.D.
33.5 minutes in 5 audio sections

Quick Take Vol. 84

0.75 CMEs
When should you taper a benzodiazepine, and how slowly? Does semaglutide reverse metabolic risk in schizophrenia patients on clozapine or olanzapine? Is EPA effective for TRD? Can brief psychotherapy enable safe antidepressant discontinuation? Is a ketogenic diet effective for depression and other psychiatric conditions?
Faculty: Scott R. Beach, M.D., Oliver Freudenreich, M.D., F.A.C.L.P., Derick E. Vergne, M.D., Paul Zarkowski, M.D., James Phelps, M.D.
47.02 minutes in 5 audio sections

Managing Catatonia: From Clinical Assessment to Effective Intervention – Interview

0.50 CMEs
A discussion on catatonia assessment and management, covering diagnostic approaches including the Bush-Francis scale, differentiating catatonia from psychosis and deception, lorazepam challenge protocols, treatment strategies including benzodiazepines and ECT, and relapse prevention.
Scott R. Beach, M.D.
Harvard Medical School
30.15 minutes of audio interview

Quick Take Vol. 83

0.75 CMEs
When should you consider high-dose olanzapine instead of clozapine for treatment-resistant schizophrenia? How effective is aripiprazole augmentation versus switching strategies in older adults with depression? Can GLP-1 receptor agonists elevate lithium levels? Should inflammatory markers guide antidepressant selection? Is adjunctive propranolol effective for panic disorder?
Faculty: Scott R. Beach, M.D., Oliver Freudenreich, M.D., F.A.C.L.P., Paul Zarkowski, M.D., James Phelps, M.D., Derick E. Vergne, M.D.
38.56 minutes in 5 audio sections

Quick Take Vol. 82

0.50 CMEs
What are the six key tips for switching oral antipsychotics? Does deprescribing antipsychotics after delirium improve outcomes in older adults? Why is xylazine overdose difficult to treat? What does the PAX-D study reveal about pramipexole for depression? Do bioequivalent medications always produce equivalent clinical results?
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P., Scott R. Beach, M.D., David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Paul Zarkowski, M.D., Derick E. Vergne, M.D.
36.44 minutes in 5 audio sections

Quick Take Vol. 81

0.50 CMEs
Can ondansetron improve negative symptoms in schizophrenia? Will lithium orotate prevent or reverse Alzheimer's disease? What predicts treatment response in bipolar disorder? Should we increase SSRI doses or try alternative strategies for inadequate response? Is trazodone safe for treating insomnia in alcohol use disorder?
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P., Scott R. Beach, M.D., Kristin Raj, M.D., Paul Zarkowski, M.D., David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M.
36.33 minutes in 5 audio sections

Quick Take Vol. 80

0.75 CMEs
How effective is the new antipsychotic KarXT using the number needed to treat metric? Can bright light therapy effectively treat bipolar depression without causing mania? Does IV haloperidol really increase cardiac risks as commonly believed? Can varenicline help reduce alcohol intake in people with alcohol use disorder? Does ashwagandha extract improve cognitive function in mild cognitive impairment?
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P., Kristin Raj, M.D., Scott R. Beach, M.D., David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., Derick E. Vergne, M.D.
39.35 minutes in 5 audio sections
1

Explore our library of over 440 video lectures, podcasts, research summaries and expert interviews.